Tracking the impact of biosimilars
Biosimilars make up almost
25% of spend
In spaces where there is an originator biologic, biosimilars now make up almost 25% of spend. Find out when — and why — we expect to see the impact of biosimilar adalimumab and other biologics on pharmaceutical spend in our latest forecast.
Projected overall drug price inflation rate for Jan. 1 – Dec. 31, 2024
Gain access now
Plan for 2024 with our new projections and insights. Download the latest drug budget forecasts to inform your pharmacy planning.
Gain actionable insights from our new report.
Pharmacy program participants
Enjoy exclusive access to companion resources and additional information
Access detailed price projections
Read the executive summary
Read and share the letter to the C-suite
Access the forecasted timetable and approvals
Read about upcoming changes
Advocacy in action — Numerous aspects of pharmaceutical policy and pharmacy practice remain the subject of existing bills, laws and regulations regarding safety, quality, and of course, cost. Read about our advocacy efforts concerning some of the most critical policy issues covered in the first half of 2023, as well as areas requiring scrutiny in the near term.
Find out how to use the report. This guide provides an overview on how to best utilize and optimize the Drug Budget Forecast reporting solution.
Experts will provide insights into advancements in oncology therapy including CAR-T, new drug approvals and other topics. Additionally, we will discuss practice challenges related to current drug shortages of generic injectable cancer agents.
During this session, pharmacy experts will provide insights about operationalizing specialty medications from the payer and provider perspectives. We will discuss general best practices as well as specific drugs and what factors to consider regarding biosimilar adoption.